We are live on ! Find out more
WIM

Woodford Investment Management Portfolio holdings

AUM $310M
1-Year Est. Return 17.41%
This Fund
S&P 500
This Quarter Est. Return
-14.44%
1 Year Est. Return
-17.41%
3 Year Est. Return
-27.14%
5 Year Est. Return
+68.29%
10 Year Est. Return
–
AUM
$591M
AUM Growth
-$648M
Cap. Flow
-$388M
Cap. Flow %
-65.56%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
1
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
EVFM
Evofem Biosciences, Inc. Common Stock
EVFM
+$11.3M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$149M
2
ALKS icon
Alkermes
ALKS
+$96.3M
3
BIIB icon
Biogen
BIIB
+$70.9M
4
PRTA icon
Prothena Corp
PRTA
+$32.4M
5
TBPH icon
Theravance Biopharma
TBPH
+$24.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBPH icon
1
Theravance Biopharma
TBPH
$877M
$199M 33.59%
12,159,980
-1,219,999
-9% -$24.7M
AUTL
2
Autolus Therapeutics
AUTL
$562M
$187M 31.58%
11,594,234
-447,185
-4% -$10M
PRTA icon
3
Prothena Corp
PRTA
$459M
$92.7M 15.69%
8,773,790
-3,150,824
-26% -$32.4M
EVFM
4
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$91.2M 15.43%
915,589
+146,007
+19% +$11.3M
NCNA
5
NuCana
NCNA
$6.12M
$22M 3.72%
424
-222
-34% -$15.2M
AGIO icon
6
Agios Pharmaceuticals
AGIO
$1.93B
– –
-2,214,459
Closed -$149M
ALKS icon
7
Alkermes
ALKS
$8.25B
– –
-2,639,676
Closed -$96.3M
BIIB icon
8
Biogen
BIIB
$30.7B
– –
-300,040
Closed -$70.9M

Similar funds

LCM
Lucha Capital Management San Francisco, California $327M AUM 2.87% 1-Year Est. Return
GWA
Guidant Wealth Advisors Palatine, Illinois $269M AUM 2.79% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
IPC
Invesco Private Capital New York $365M AUM 8.08% 1-Year Est. Return
AEPG
American Economic Planning Group Warren, New Jersey $367M AUM 2.51% 1-Year Est. Return
AR
Argyll Research Wilmington, Delaware $377M AUM 4.86% 1-Year Est. Return
KCM
Keywise Capital Management Grand Cayman, Cayman Islands $220M AUM 21.27% 1-Year Est. Return
COI
Capital One Investing Mclean, Virginia $430M AUM 3.49% 1-Year Est. Return

Woodford Investment Management's Q2 2019 Portfolio in Review

As of Q2 2019, Woodford Investment Management held 8 positions worth $591M, down 52% from $1.24B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Woodford Investment Management withdrew a net $388M in Q2 2019, closing 3 positions and reducing 4 holdings. Its most notable exit was Agios Pharmaceuticals, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Woodford Investment Management added an estimated $11.3M to Evofem Biosciences, Inc. Common Stock.

  • Woodford Investment Management added most to Evofem Biosciences, Inc. Common Stock in Q2 2019, an estimated $11.3M increase.
  • Woodford Investment Management's biggest Q2 2019 reduction was Prothena Corp, cutting an estimated $32.4M.
  • Woodford Investment Management fully exited Agios Pharmaceuticals in Q2 2019, selling an estimated $149M.
  • Woodford Investment Management's ten largest holdings make up 100% of its $591M portfolio in Q2 2019.
  • Woodford Investment Management opened 0 new positions and closed 3 in Q2 2019.
  • Woodford Investment Management's portfolio value fell 52% quarter-over-quarter to $591M.

Based on Woodford Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.